Health · Pharma & Biotech · 2 hrs ago
Amplia receives ethics approval for pancreatic cancer drug trial
Amplia Therapeutics has ethics approval to begin a trial of its drug narmafotinib with chemotherapy in people with metastatic pancreatic cancer.
The company plans to recruit patients at three Australian clinical trial sites for the ACCENT-Mini study.
Narmafotinib blocks a protein called FAK, which can help form dense tissue around tumours; Amplia hopes this may help chemotherapy reach cancer cells.
The trial follows an earlier study that reported a 36 per cent confirmed tumour response rate, but ACCENT-Mini will test a daily dosing schedule to find a safe and effective dose.
Safety and drug-level data are expected in early 2027, according to the company.
Amplia plans to use those results in a submission to the US Food and Drug Administration for a larger study, if the findings support moving ahead.
Amplia Therapeutics received ethics approval to begin the ACCENT-Mini trial of narmafotinib with chemotherapy in patients with metastatic pancreatic cancer.
The trial will recruit patients at three selected Australian clinical trial sites.
It will assess daily dosing to determine a safe and effective regimen.
Amplia expects safety and pharmacokinetic data in late Q1 or early Q2 of 2027.
The company plans to use the data in a protocol submission to the US Food and Drug Administration for a larger registrational study.
- Who
- Amplia Therapeutics, which is testing its drug candidate narmafotinib.
- What
- The company received ethics approval for the ACCENT-Mini clinical trial, combining narmafotinib with chemotherapy.
- When
- The approval was reported on November 19, 2026. Data are expected in late Q1 or early Q2 of 2027.
- Where
- Three selected clinical trial sites in Australia.
- Why
- The trial will assess the safety and effective dose of daily narmafotinib alongside chemotherapy in metastatic pancreatic cancer.
This story does not have two clearly opposing sides.
Amplia’s ethics approval for the ACCENT-Mini trial was reported.
Amplia expects safety and pharmacokinetic data from the study.
- Trial
- ACCENT-Mini
- Drug candidate
- Narmafotinib
- Disease
- Metastatic pancreatic cancer
- Trial sites
- Three selected sites in Australia
- Expected data
- Late Q1 or early Q2 of 2027
What people are saying
We are delighted to have received ethics approval for this important study of narmafotinib in metastatic pancreatic cancer, a devastating disease where patients have limited treatment options.
Based on our preclinical studies and clinical experience to date, we believe that combining chemotherapy with daily-dosed narmafotinib has the potential to deliver improved outcomes, and we look forward to exploring this in ACCENT-Mini.